GLP Spot Trend Scout: June 13, 2026

This is the daily trend scout report for GLP Spot, covering rising search interest, GSC near-miss pages, stale content, and uncovered topic gaps as of June 13, 2026 — five days after ADA 2026 concluded and a wave of new studies hit the news cycle.

What changed since yesterday's scout: All three high-priority articles recommended on June 12 (CVS Zepbound reversal, GLP-1 and MASH, GLP-1 and tattoos) have been written. Three major studies published on June 13 create new content opportunities: (1) GLP-1 users decreasing physical activity (ENDO 2026), (2) apitegromab preserving muscle on GLP-1s (Nature Medicine), and (3) semaglutide slowing biological aging (Nature Communications). Additionally, the Wegovy pill was approved in the UK and Zenagamtide Phase 2 T2D data surfaced from ADA 2026.

1. Rising Search Trends (Google Trends Signal)

Tier 1 — High-Volume, Accelerating

Query Cluster	Why Rising	Our Coverage
GLP-1 and exercise / Ozempic exercise study	ENDO 2026 study (June 13) shows GLP-1 users' daily steps drop from 5,047→4,487; major news coverage today	Exercise Guide — refreshed June 13 with muscle preservation data; add this study
Apitegromab muscle preservation / GLP-1 muscle loss drug	Nature Medicine publication June 13: apitegromab + Mounjaro preserves 1.9 kg more muscle; major press	None — topic gap (high priority)
Semaglutide aging / Ozempic anti-aging	UC study in Nature Communications (June 11): semaglutide slows biological aging 9% per DunedinPACE clock; surfacing in mainstream media now	None — topic gap (high priority)
Wegovy pill UK approval	MHRA approved Wegovy pill June 11; first European market; private prescription in weeks	Wegovy Pill Doses & Availability — needs UK approval update
GLP-1 breast cancer risk	Penn/ASCO study: women on GLP-1s had ~30% lower breast cancer risk; major news	GLP-1 Cancer Prevention — could expand
GLP-1 non-responders / Ozempic not working	Stanford study in Genome Medicine: 10% of population has PAM variants making GLP-1s less effective; Medicare Bridge amplifies urgency	None — topic gap

Tier 2 — Moderate-Volume, Growing

Query Cluster	Why Rising	Our Coverage
Zenagamtide type 2 diabetes / amycretin T2D	Phase 2 ADA data: 40 mg zenagamtide dropped HbA1c 1.56 points more than placebo; 76% reached HbA1c ≤6.5%	Zenagamtide vs Ozempic — updated June 10, needs T2D data
Retatrutide TRIUMPH-1 long-term	CNBC June 13: Lilly CEO says retatrutide enables people with BMI>40 to reach healthy weight; 28% weight loss at 80 weeks	Retatrutide Guide — updated May 26, needs TRIUMPH-1 update
Foundayo real-world reviews	Now 10+ weeks since launch; Reddit/Harvest reviews showing results; CVS formulary addition	Foundayo Guide — updated May 15, needs real-world section
GLP-1 and gallstones	Growing awareness of rapid weight loss → gallstone risk; patients searching after recent news	None — topic gap
GLP-1 and creatine / BCAA	Muscle preservation concern driving supplement stacking searches	None — topic gap (noted June 12, still uncovered)
GLP-1 and dating	Lifestyle content gap; body changes affect dating dynamics	None — topic gap (noted June 12, still uncovered)
GLP-1 and melatonin / ashwagandha	Supplement stacking with GLP-1s; sleep + stress management	None — topic gaps (noted June 12, still uncovered)

Tier 3 — Emerging, Low-Volume but Early

Query Cluster	Why Rising	Our Coverage
Petrelintide / Zealand Pharma amylin	Phase 2 data at ADA: ~11% weight loss, less vomiting than GLP-1s; Roche partnership; CNBC coverage June 13	None — topic gap
Pfizer Metsera monthly shot	$10B acquisition; monthly dosing potential; mid-stage data at ADA	None — topic gap
Amgen quarterly GLP-1	Monthly/quarterly dosing potential; differentiated from weekly shots	None — topic gap
GLP-1 carnivore diet	Keto/carnivore crossover; protein-heavy diet + GLP-1	None — topic gap (noted June 12)

2. GSC Near-Miss Pages

Since we do not have live GSC API access for this automated scout, the following near-miss candidates are identified from the June 12 scout plus inferred opportunities from the rapid content creation cadence:

Priority Near-Misses (Inferred from Content Gaps + Search Patterns)

Article	Likely Target Keyword	Action Needed
Exercise on GLP-1	"glp-1 exercise study 2026" / "ozempic exercise decline"	Freshly updated June 13 — confirm ENDO 2026 study is included
Muscle Loss Prevention	"glp-1 muscle loss prevention 2026"	Refreshed June 13 — confirm apitegromab data is included
First Week Ozempic	"first week ozempic"	Refreshed — verify oral GLP-1 guidance is present
Hair Loss GLP-1	"hair loss ozempic" / "glp-1 hair loss"	Updated June 13 with Foundayo+clinical data — verify
GLP-1 Interactions	"glp-1 interactions"	Updated — verify Foundayo, oral tirzepatide included
GLP-1 Sleep Apnea	"glp-1 sleep apnea 2026"	Updated June 13 — verify Zepbound OSA approval included
GLP-1 Liver Health	"glp-1 fatty liver" / "survodutide mash"	Updated June 12 — verify retatrutide liver data included
Mounjaro vs Ozempic	"mounjaro vs ozempic"	Updated June 12 with Wegovy HD, Foundayo context
CVS Caremark Zepbound Coverage	"cvs zepbound 2026"	New article June 12 — first-mover advantage; ensure indexed

3. Stale Articles (68+ Days Without Update)

Total articles: 282 | Articles stale 68+ days: ~105 (37%)

Since June 12, the following articles were refreshed: GLP-1 Exercise, Muscle Loss Prevention, Hair Loss, GLP-1 Sleep, GLP-1 Sleep Apnea, GLP-1 Liver Health, Ozempic vs Mounjaro, First Week Ozempic, GLP-1 Interactions. This reduced the stale count from ~115 to ~105.

Critical Staleness (100+ days)

Article	Days Stale	Why It Needs Refresh
Exercise on GLP-1	~~106 days~~ REFRESHED June 13	✅ Verify ENDO 2026 study included
Hair Loss GLP-1	~~106 days~~ REFRESHED June 13	✅ Verify Foundayo data included
First Week Ozempic	~~109 days~~ REFRESHED	✅ Verify oral GLP-1 guidance included

All three critical-staleness articles are now refreshed. The remaining stale articles are down to the April 4-5 batch (now ~70 days stale).

High-Priority Stale (69-70 days — April 4-5 batch)

Lower commercial intent, but still need attention:

Article	Days Stale	Why It Needs Refresh
GLP-1 Heart Health	70 days	Needs retatrutide cardiovascular data, SELECT follow-up, new per month data
GLP-1 Kidney Health	70 days	Needs FLOW trial follow-up, semaglutide CKD data
Nausea Triggers	70 days	Foundational; high search volume
Constipation Solutions	70 days	Foundational; high search volume
Fatigue and Energy	70 days	Frequently searched; needs Foundayo/Wegovy pill data
Tirzepatide Price	70 days	Needs 2026 pricing, Foundayo, Medicare bridge, CVS formulary
Mounjaro Savings Card	70 days	Program terms may have changed
Zepbound Savings Card	70 days	May have updated offers
GLP-1 Insurance Coverage	Updated June 12 (1 day ago)	Recent — verify CVS reversal included
Semaglutide vs Tirzepatide	70 days	Needs 2026 pricing, oral options
GLP-1 Bone Health	70 days	Growing interest with aging population
GLP-1 Gallbladder	70 days	Growing interest — gallstone risk awareness
GLP-1 Pancreatitis	70 days	Safety topic; needs current data

4. New Topic Gaps (Zero Coverage)

High-Priority Gaps (Strong Search Intent + Revenue Potential)

Proposed Article	Search Intent	Priority	Revenue Angle
GLP-1 and Muscle Preservation: Apitegromab and the Future of Lean Mass on GLP-1s	"apitegromab", "glp-1 muscle loss drug", "mounjaro muscle preservation"	Critical — Nature Medicine June 13, massive press	Amazon: protein powders, creatine, BCAA; course/guide
Does Ozempic Slow Aging? Semaglutide and Biological Age	"ozempic anti-aging", "semaglutide aging", "does ozempic slow aging"	Critical — Nature Communications June 11, surfacing now	High-volume query; affiliate: supplements, NAD+
Why Ozempic Doesn't Work for Everyone: GLP-1 Non-Responders	"ozempic not working", "glp-1 non-responder", "why doesn't wegovy work"	High — Stanford study, Medicare Bridge urgency	Internal links; telehealth affiliate
GLP-1 Gallstones: Risk, Prevention, and What to Watch For	"glp-1 gallstones", "ozempic gallbladder", "weight loss gallstones"	High — rising search awareness	Internal links; health education
Zenagamtide (Amycretin) for Type 2 Diabetes: Phase 2 Data	"zenagamtide type 2 diabetes", "amycretin t2d"	High — fresh ADA data; specific T2D angle	Internal links to zenagamtide guide
GLP-1 Breast Cancer Risk Reduction: What the Data Says	"glp-1 breast cancer", "ozempic cancer"	High — Penn/ASCO study, high credibility	Internal links; general health

Medium-Priority Gaps (Growing Interest)

Proposed Article	Search Intent	Priority
GLP-1 Exercise Decline: Why Activity Drops and How to Fix It	"ozempic exercise study", "glp-1 not exercising", "wegovy activity"	Medium — ENDO 2026 study June 13
Wegovy Pill UK Approval: What It Means for Global Access	"wegovy pill uk", "semaglutide tablets uk"	Medium — UK approval
Next-Gen GLP-1s: Monthly Shots, Amylin, and What's Coming	"pfizer monthly glp-1", "amgen quarterly glp-1", "petrelintide", "new glp-1 drugs 2026"	Medium — post-ADA pipeline roundup
GLP-1 and Melatonin / Ashwagandha	"glp-1 melatonin", "ozempic ashwagandha"	Medium — supplement stacking
GLP-1 and Dating	"glp-1 dating", "ozempic dating"	Medium — lifestyle content gap
GLP-1 and Creatine / BCAA	"glp-1 creatine", "ozempic bcaa"	Medium — bodybuilding niche
GLP-1 Carnivore Diet	"glp-1 carnivore", "ozempic carnivore diet"	Medium — keto/carnivore crossover

Lower-Priority Gaps

Proposed Article	Search Intent	Priority
Retatrutide vs Bariatric Surgery: Is the Gap Closing?	"retatrutide vs surgery", "glp-1 vs bariatric"	Low — speculative until FDA approval
Foundayo Real-World Results: 10+ Week Check-In	"foundayo reviews", "orforglipron results"	Low — still early for definitive data

5. Articles Filled Since June 12 Scout

These topic gaps from the June 12 scout now have coverage:

Topic	Article Written	Date
CVS Caremark Zepbound Coverage Reversal	cvs-caremark-zepbound-coverage-2026.md	June 12
GLP-1 and MASH/MASLD	glp1-mash-masld-survodutide.md	June 12
GLP-1 and Tattoos	glp1-tattoos-safety-healing.md	June 12
GLP-1 Exercise Refresh	exercise-glp1.md	June 13
Hair Loss Refresh	hair-loss-glp1.md	June 13
First Week Ozempic Refresh	first-week-ozempic.md	June 13
GLP-1 Sleep Refresh	glp-1-sleep.md	June 13
GLP-1 Sleep Apnea Refresh	glp-1-sleep-apnea.md	June 13
Muscle Loss Prevention Refresh	glp-1-muscle-loss-prevention.md	June 13
GLP-1 Interactions Refresh	glp-1-interactions.md	June 13
Ozempic vs Mounjaro Refresh	ozempic-vs-mounjaro.md	June 12
GLP-1 Liver Health Refresh	glp-1-liver-health.md	June 12

6. Internal Linking Opportunities

New articles that should receive backlinks from older content:

Recent Article	Older Articles That Should Link to It
CVS Zepbound Coverage	GLP-1 Insurance, Zepbound Cost, Mounjaro vs Zepbound
GLP-1 and MASH/MASLD	Liver Health, Survodutide Guide, NASH/Survodutide Coverage
GLP-1 and Tattoos	GLP-1 Immune System, GLP-1 Cosmetic Procedures

Cross-link opportunities identified:

Article A	Article B	Connection
Exercise Guide	Muscle Loss Prevention	Exercise + muscle preservation: two sides of same coin
Sleep Guide	Sleep Apnea, Melatonin/Ashwagandha (future)	Sleep ecosystem
GLP-1 Interactions	Supplements Guide	Supplement safety

7. Content Priority Recommendations

Based on this scout, the recommended action order:

Write First (New Articles)

GLP-1 and Muscle Preservation: Apitegromab — Nature Medicine study, massive press, high-intent query
Semaglutide and Biological Aging — Nature Communications, anti-aging angle is explosive
GLP-1 Gallstones — rising search awareness, fills a safety/education gap
GLP-1 Non-Responders — Stanford study, high clinical relevance, Medicare Bridge timeliness
Zenagamtide (Amycretin) for T2D — fresh ADA Phase 2 data

Refresh First (Stale Articles)

GLP-1 Heart Health — 70 days stale, needs retatrutide CV data
Nausea Triggers & Management — 70 days stale, foundational high-volume article
Constipation Solutions — 70 days stale, foundational high-volume article
Fatigue and Energy — 70 days stale, frequently searched
Tirzepatide Price — 70 days stale, commercial intent
Semaglutide vs Tirzepatide — 70 days stale, comparison traffic
GLP-1 Kidney Health — 70 days stale, FLOW trial data

Optimize (GSC Near-Misses)

Exercise Guide — verify ENDO 2026 study included
Muscle Loss Prevention — verify apitegromab data included
Hair Loss — verify Foundayo data included
First Week Ozempic — verify oral GLP-1 guidance included

8. Summary Stats

Metric	Count	Change from June 12
Total articles in library	282	+3 (CVS, MASH, Tattoos)
Articles stale 70+ days (April 4 batch)	~105 (37%)	Down from ~115 (41%) thanks to 12 refreshes
New topic gaps identified	14 high/medium	5 from June 12 now filled, ~7 new
GSC near-miss candidates	9	Stable (no live GSC data refresh)
Recommended new articles	5	Apitegromab, Aging, Gallstones, Non-responders, Zenagamtide T2D
Recommended refreshes	7	Heart, Nausea, Constipation, Fatigue, Tirzepatide Price, Sema vs Tirz, Kidneys

This scout report is an internal editorial document identifying content opportunities. It does not constitute medical advice. Topic gap analysis is based on search trend signals and existing coverage inventory as of June 13, 2026. GSC near-miss analysis is inferred from the June 12 scout and would benefit from live GSC API data refresh.